Arch Venture Partners raises US$1.85B for its biggest-ever fund | FI SENSE


Biotech investment specialist Arch Venture Partners has hit a $1.85bn final close for its eleventh flagship fundraise, less than a year after closing $1.46bn predecessor.

ARCH has raised ten venture funds totaling over $3 billion and has invested in the earliest venture capital rounds for more than 150 companies. ARCH investors include major corporations, pension funds, endowment funds, financial institutions, and private investors.

Early stage ARCH investments have included Illumina, Alnylam Pharmaceuticals, Juno Therapeutics, Receptos, Agios Pharmaceuticals, Vir Biotechnology, Sage Therapeutics, bluebird bio, Codiak Biosciences, Denali Therapeutics, GRAIL, Karuna Therapeutics, Beam Therapeutics, Lyell Immunopharma, Sana Biotechnology, Brii Biosciences, Twist Biosciences, Aviron, Ikaria, Gossamer Bio, Fate Therapeutics, Array Biopharma, Adolor, Quanterix, 908 Devices, Unity Biotechnology, Hua Medicine, deCODE Genetics, Homology Medicines and others.

It the latest fund, which was raised during the first lockdown in April 2019, the life sciences investor ARCH Venture Partners raised $1.46 billion in funding across two funds to finance new tech development. The two funds, ARCH Venture Fund X and ARCH Venture Fund X Overage, followed the firm’s long line of investment vehicles dedicated to invest in early-stage biotechnology companies.

ARCH Venture Partners invests in advanced technology companies and is one of the largest early stage technology venture firms in the United States. The firm is a recognized leader in commercializing technologies developed at academic institutions, corporate research groups and national laboratories. ARCH invests primarily in companies it co-founds with leading scientists and entrepreneurs, bringing innovations in life sciences and physical sciences to market.



Leave a Reply

Your email address will not be published. Required fields are marked *

FI Sense